Incidence and Outcome of Atypical Manifestations of Chronic Graft-Versus-Host Disease - Results From a Retrospective Single-Center Analysis
Source : https://www.sciencedirect.com/science/article/abs/pii/S2666636723015555?via=ihub
Chronic graft-versus-host disease (cGvHD) is the leading cause of late non-relapse mortality (NRM) after allogeneic stem cell transplantation (alloHSC...
In summary, atypical cGvHD is more common than previously estimated and has both, similarities with and differences from NIH-defined cGvHD. In particular, the increased NRM and a subset of patients with only atypical cGvHD point to the urgent need to capture these manifestations in cGvHD cohorts, including analysis of treatment outcome.
Sclerotic-type chronic graft-versus-host disease exhibits activation of Th1 and OX40 cytokines - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37742913/
Sclerotic-type cutaneous chronic graft-versus-host disease (ScGvHD) is a severe complication of allogeneic hematopoietic stem cell transplantation, with profound morbidity. A dearth of effective, targeted treatment options necessitates further investigation into...
Cell-type deconvolution revealed significant representation of macrophages and vascular endothelial cells. ScGvHD in young patients may therefore be characterized by strong Th1-related upregulation with a unique TSLP-OX40 signature, suggesting new therapeutic avenues for this devastating disease.
ER stress: an emerging regulator in GVHD development
Source : https://www.frontiersin.org/articles/10.3389/fimmu.2023.1212215/full
Allogeneic hematopoietic cell transplantation (allo-HCT) is a promising therapeutic option for hematologic malignancies. However, the clinical benefits of allo-HCT are limited by the development of complications including graft-versus-host disease (GVHD)....
In this review, we summarize the current literature regarding the contribution of ER stress response to the development of GVHD in both hematopoietic and non-hematopoietic cells. Additionally, we explore the potential therapeutic implications of targeting UPR to enhance the effectiveness of allo-HCT for patients with hematopoietic...
Use of ropeginterferon in inducing graft versus myelofibrosis effect in post-transplant myelofibrosis relapse - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37744628/
Here, we describe a patient with post-transplant myelofibrosis with chronic graft-versus-host disease (GVHD), who showed successful molecular remission with ropeginterferon with 100% donor chimerism without any flare up of GVHD....
Here, we describe a patient with post-transplant myelofibrosis with chronic graft-versus-host disease (GVHD), who showed successful molecular remission with ropeginterferon with 100% donor chimerism without any flare up of GVHD.
Thiotepa-Busulfan-Fludarabine Compared to Treosulfan-Based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: a Study From the Acute Leukemia Working Party of the EBMT
tween 2010 and 2020. A total of 1123 patients met the inclusion criteria (968 received TBF and 155 received Treo). A 1:1 matched-pair analysis was performed on 142 TBF and...
Relapse incidence at 2 years was not statistically different in the 2 groups (16% and 18% in TBF and Treo, respectively; P = 0.9). Leukemia-free survival, overall survival, and GVHD-free, relapse-free survival was 65% versus 68% (P = 0.6), 73% versus 76% (P = 0.5), and 54% versus 53% (P = 0.8) in TBF versus Treo,...